News und Analysen
Reckitt Benckiser Standardizes on Veeva Commercial Cloud Applications to Advance Digital Excellence Globally
Veeva Systems (NYSE: VEEV) today announced that RB (Reckitt Benckiser), a leading provider of consumer hygiene, health, and nutrition products, is using Veeva CRM and Veeva Vault PromoMats to
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2020 and provided guidance for 2021. For the quarter, revenue was $791.0
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021
NanoString to Webcast Presentation from the 10th Annual SVB Leerink Global Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a
Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY®, the companies’
Sensorion : A Chardan Top Pick for 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
BIOCORP Signs Two New Partnerships With Mallya Technology
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today
Mehr als 250 Unternehmen transformieren regulatorische Abläufe mit Veeva Vault RIM-Anwendungen
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass mehr als 250 Unternehmen Veeva Vault RIM-Anwendungen für das durchgängige Management regulatorischer Daten nutzen. Eine wachsende Zahl von
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.55 billion for the first quarter ended Jan. 31, 2021, an increase of 14% compared to the first quarter of 2020 and up 11% on a core(
Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
PerkinElmer to Present at Cowen Health Care Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41st Annual Cowen Health Care Conference on
More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications
Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging
More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications
Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging
VALBIOTIS autorisiert den Start von HEART, der multizentrischen klinischen Phase-II-Studie zu TOTUM-070 zur Senkung des LDL-Cholesterinspiegels
VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME, französischer Aktiensparplan zur Finanzierung von KMUs) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit
Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments
Regulatory News:
Sensorion (Paris:ALSEN)(FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME, French equity savings plan for the financing of SMEs) (Paris:ALVAL), a Research & Development company committed to scientific innovation
Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports biomarker data from the ongoing
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® (Immune Globulin Intravenous
Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions
Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 4:30 p.m. ET on Thursday, February 25, 2021, to discuss its financial and
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2020.
Record fourth quarter revenue reflects a strong close to 2020:
-
Revenue of $953
Dexcom Reports Fourth Quarter and Fiscal Year 2020 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2020.
Fourth Quarter 2020 Financial Highlights:
-
Revenue grew 23%